{
  "Country": "DE",
  "PICOs": [
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy.",
      "Intervention": "New medicine under assessment",
      "Comparator": "Docetaxel (only for patients with PD-L1 negative tumours)",
      "Outcomes": "Progression-free survival, overall survival, health-related quality of life, side effects"
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy.",
      "Intervention": "New medicine under assessment",
      "Comparator": "Pemetrexed (only for patients with PD-L1 negative tumours and except in cases of predominantly squamous histology)",
      "Outcomes": "Progression-free survival, overall survival, health-related quality of life, side effects"
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy.",
      "Intervention": "New medicine under assessment",
      "Comparator": "Nivolumab (only for patients with PD-L1 expressing tumours)",
      "Outcomes": "Progression-free survival, overall survival, health-related quality of life, side effects"
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy.",
      "Intervention": "New medicine under assessment",
      "Comparator": "Pembrolizumab (only for patients with PD-L1 expressing tumours)",
      "Outcomes": "Progression-free survival, overall survival, health-related quality of life, side effects"
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy.",
      "Intervention": "New medicine under assessment",
      "Comparator": "Atezolizumab",
      "Outcomes": "Progression-free survival, overall survival, health-related quality of life, side effects"
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy.",
      "Intervention": "New medicine under assessment",
      "Comparator": "Docetaxel in combination with nintedanib (only for patients with PD-L1 negative tumours and adenocarcinoma histology)",
      "Outcomes": "Progression-free survival, overall survival, health-related quality of life, side effects"
    }
  ],
  "SourceType": "hta_submission"
}